Spruce Street Capital LP Invests $34.59 Billion in Dianthus Therapeutics, Inc. $DNTH

Spruce Street Capital LP bought a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) in the second quarter, HoldingsChannel.com reports. The firm bought 354,816 shares of the company’s stock, valued at approximately $34,587,464,000. Dianthus Therapeutics comprises 6.8% of Spruce Street Capital LP’s holdings, making the stock its 6th largest holding.

Other institutional investors also recently modified their holdings of the company. Elevation Point Wealth Partners LLC acquired a new position in shares of Dianthus Therapeutics in the second quarter valued at about $868,000. Quantbot Technologies LP acquired a new stake in Dianthus Therapeutics in the 2nd quarter worth about $174,000. Emerald Investment Advisers LLC bought a new stake in Dianthus Therapeutics in the 2nd quarter valued at about $2,579,000. E Fund Management Co. Ltd. bought a new stake in Dianthus Therapeutics in the 2nd quarter valued at about $497,000. Finally, Eagle Health Investments LP bought a new stake in Dianthus Therapeutics in the 2nd quarter valued at about $12,803,000. Institutional investors own 47.53% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Guggenheim reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wall Street Zen upgraded Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Truist Financial boosted their price target on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. Finally, HC Wainwright raised their price objective on Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $124.27.

Insider Buying and Selling

In related news, EVP Simrat Randhawa sold 26,530 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the sale, the executive vice president owned 4,000 shares in the company, valued at approximately $362,480. This trade represents a 86.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Adam M. Veness sold 30,000 shares of Dianthus Therapeutics stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the completion of the transaction, the senior vice president directly owned 30,000 shares in the company, valued at $2,424,000. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 287,084 shares of company stock worth $29,615,923. 3.02% of the stock is owned by company insiders.

Dianthus Therapeutics Stock Down 0.9%

DNTH stock opened at $110.07 on Tuesday. The company has a market cap of $6.02 billion, a PE ratio of -26.52 and a beta of 1.22. The business has a 50-day simple moving average of $101.30 and a 200 day simple moving average of $85.62. Dianthus Therapeutics, Inc. has a 52 week low of $22.81 and a 52 week high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The firm had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. On average, analysts anticipate that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current fiscal year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.